TABLE 2

Demographics and Resource Use in Patients With KD by IVIg Response

DemographicsOverall (N = 430)Responders (n = 349)Nonresponders (n = 81)Pa
Age, mo, n (%).74
 <1289 (20.7)74 (21.2)15 (18.5)
 12–2376 (17.7)60 (17.2)16 (19.8)
 24–59163 (37.9)135 (38.7)28 (34.6)
 ≥60102 (23.7)80 (22.9)22 (27.2)
Female sex173 (40.2)144 (41.3)29 (35.8).37
Primary payer, n (%).79
 Commercial288 (67.0)233 (66.8)55 (67.9)
 Government140 (32.6)114 (32.7)26 (32.1)
 None2 (0.5)2 (0.6)0
Race, n (%).73
 White209 (48.6)170 (48.7)39 (48.1)
 African American63 (14.7)49 (14.0)14 (17.3)
 Asian American62 (14.4)53 (15.2)9 (11.1)
 Other, declined, or unknown38 (8.8)31 (8.9)7 (8.6)
 Multiracial29 (6.7)21 (6.0)8 (9.9)
 Hispanic26 (6.0)22 (6.3)4 (4.9)
Resource use, median (IQR)
 Total hospital LOS, d3.2 (2.5–4.9)3.0 (2.1–4.1)4.9 (4.1–7.6)<.001
 Time from admission to IVIg treatment start, h20 (9–41)20 (8–40)23 (9–48).54
 Hospital LOS after first IVIg treatment completed, h42 (31–59)37 (28–52)80 (65–122)<.001
  • IQR, interquartile range; —, not applicable.

  • a P values were calculated by using the Wilcoxon rank test for continuous outcomes and Pearson’s χ2 test (or Fischer’s exact test, when appropriate) for categorical outcomes.